pf4455242
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2009 (NCT00938301)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Kappa opioid receptorANTAGONIST
OPRK1 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 2-methyl-n-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine
- 2-methyl-n-(2'-(pyrrolidinyl-1-ylsulfonyl)-(1,1'-biphenyl)-4-yl)propan-1-amine
- pf-04455242
- pf-04455242
- pf-04455242
- pf4455242
- pf 4455242
- pf-4455242
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00988949 | Phase 1 | Nov 1, 2009 | Pfizer |
| NCT00939887 | Phase 1 | Sep 1, 2009 | Pfizer |
| NCT00956956 | Phase 1 | Sep 1, 2009 | Pfizer |
| NCT00938301 | Phase 1 | Apr 1, 2009 | Pfizer |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 4 | 4 | 1 | 2009 |
1 organizations
Page 1 / 1